1. Home
  2. ARVN

as 06-05-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Founded: 2015 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 456.2M IPO Year: 2018
Target Price: $20.53 AVG Volume (30 days): 2.2M
Analyst Decision: Buy Number of Analysts: 21
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.65 EPS Growth: N/A
52 Week Low/High: $5.90 - $34.11 Next Earning Date: 07-29-2025
Revenue: $426,900,000 Revenue Growth: 498.74%
Revenue Growth (this year): 2.83% Revenue Growth (next year): -46.51%

ARVN Daily Stock ML Predictions

Stock Insider Trading Activity of Arvinas Inc. (ARVN)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Berkowitz Noah ARVN Chief Medical Officer Mar 18 '25 Sell $8.59 8,658 $74,372.22 110,023

Share on Social Networks: